IMR Press / FBS / Volume 2 / Issue 1 / DOI: 10.2741/S40

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

SNPs: At the origins of the databases of an innovative biotechnology tool
Show Less
1 Clinical Science at South Bristol, Bristol Royal Infirmary, University of Bristol, United Kingdom
2 Charite University Hospitals, Institute of Human Genetics, Berlin, Germany
3 Laboratories for Molecular Oncogenetics, Ulm, Germany
4 Queen Medical Center, Nottingham University Hospital, United Kingdom
5 Institute of Pathology, University of Innsbruck, Austria
6 Pediatric Pathology Section, Institute of Pathology, University of Innsbruck, Austria

*Author to whom correspondence should be addressed.

Academic Editor: Consolato Sergi

Front. Biosci. (Schol Ed) 2010, 2(1), 1–4;
Published: 1 January 2010
(This article belongs to the Special Issue Progresses in heart failure diagnosis and treatment)

The discovery that DNA sequence variations can influence the response of an individual to a drug or can predict the outcome of a disease has added a new dimension to evidence-based medicine. It is clear that the goals, risks, and benefits of drug therapy can be better assessed if the underlying genome of the patient is known. The relevance of identifying patients at increased risk of adverse drug reactions, the application of genomic technologies to drug development and the clarification of the mechanisms of drug action on cells will be important targets in the therapeutic approach to medicine in the 21st century. In this review, we summarize the development of single nucleotide polymorphisms (SNPs) and give computational biological data for SNPs databases.

Back to top